

Amendments to the Specification:


On page 1, after the Title, please add the following paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed pursuant to 35 USC 371 as a United States National Phase Application of International Patent Application Serial No. PCT/US2004/010518 filed on April 6, 2004, which claims priority from 60/462,292 filed on April 11, 2003 in the United States.

On page 2, beginning at line 22, please amend the paragraph as follows:

~~P32897WO1~~ WO03/033480 (GlaxoSmithKline) relates to compounds of the formula




or a salt thereof , wherein M is a group selected from O, S, CO, NH or CH₂, L is a 2 or 3 membered alkylene chain, and the chain -M-L may be optionally substituted by one or more groups selected from methyl, ethyl, hydroxy or alkoxy and or which chain may contain a -C=C- double bond; R₁ and R₂ each independently represent hydrogen, C₁₋₆ straight or branched alkyl which may be optionally substituted by phenyl, or C₃₋₆ cycloalkyl optionally substituted by one or more C₁₋₆ alkyl groups; or R₁ and R₂ together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic ring or a 7-10 membered bridged heterocyclic ring, which rings may be optionally substituted by a phenyl group or up to 4 C₁₋₃ alkyl groups; or R₁ or R₂ may be linked to the group L or be linked as part of the substituted X on the phenyl ring to form a cyclic group; the group X may be linked to the group L to form a cyclic group which may contain an additional oxygen, a sulphur or nitrogen atom, alternatively or additionally there may be one or more substituents X selected from hydroxy, C₁₋₂ alkyl, C₁₋₂ alkoxy, halogen, C₂₋₃ alkenyl, benzyl, CR_aNOR_b wherein R_a and R_b are independently hydrogen or methyl, methoxy-methyl, methoxymethoxy or methoxyethoxy; QY is a bicyclic fused heterocyclic ring wherein Y is one ring of a

bicyclic fused heterocyclic group and which is linked via nitrogen atom therein to the phenyl ring, and substituted on the second ring Q by the group ZR₃; Z is a bond or a group selected from NH, NCH₃, O, S or CH₂; R₃ is a group selected from aryl, 2-alkenyl, cycloalkyl or 2-cycloalkenyl and which R₃ group may be optionally substituted by one or more C₁₋₃ alkyl, halo, amino, alkylamino, dialkylamino, hydroxy, C₁₋₃ alkoxy, cyano, trifluoromethyl or methylthio groups, processes for their preparation, pharmaceutical compositions containing them and to their use in medicine.

On page 3, beginning at line 27, please amend the paragraph as follows:

~~P32897WO2~~ WO03/033476 (GlaxoSmithKline) relates to a compound of the formula comprising:



a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided.